Testing (HCV)

Assay to Measure Efficacy of Hepatitis C Treatment Approved

Published in Virus Weekly, October 20th, 1997

National Genetics Institute, Culver City, California, announced that its quantitative assay (Superquant HCV) for measurement of the hepatitis C virus (HCV) has been recognized by the U.S. Food and Drug Administration (FDA) as an acceptable means to assess the efficacy of a newly approved drug for the treatment of chronic HCV infection.

In a randomized controlled Phase III study of 704 chronic Hepatitis C patients treated with either Intron A (Schering Plough, Kenilworth, New Jersey) or Infergen (Amgen Inc. Thousand Oaks, California), the Superquant HCV assay was used to assess changes in viral concentrations over the course of treatment and six months after stopping...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (1997-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry